



## Canadian spotlight 19.2: Key additions from the second half of July 2022

In the second half of July, contributing Canadian evidence-synthesis teams have shared with us four newly completed evidence syntheses which are listed in the table below. From the COVID-END inventory, these syntheses provided insight focused on public-health measures (n=4).

Taxonomy section	Title	Type of product	Date of last search (and publication)	Evidence synthesis team
<ul style="list-style-type: none"> <li>Public-health measures</li> </ul>	<a href="#">What is the effectiveness of available COVID-19 vaccines for adults, including for variants of concern and over time frames up to 120 days?</a>	Update to a living evidence synthesis	2022-07-20 (published 2022-07-20)	Health Information Research Unit, McMaster University
<ul style="list-style-type: none"> <li>Public-health measures</li> </ul>	<a href="#">What is the long-term effectiveness of available COVID-19 vaccines for adults, including for variants of concern and over time frames beyond 112 days in those with a primary series and beyond 84 days in those with a primary series and an additional dose?</a>	Update to a living evidence synthesis	2022-07-20 (published 2022-07-20)	Montreal Behavioural Medicine Centre, Concordia University
<ul style="list-style-type: none"> <li>Public-health measures</li> </ul>	<a href="#">What is the effectiveness of available COVID-19 vaccines for children and adolescents, including variants of concern?</a>	Update to a living evidence synthesis	2022-07-20 (published 2022-07-19)	Faculty of Medicine, University of Antioquia & Health Information Research Unit, McMaster University
<ul style="list-style-type: none"> <li>Public-health measures</li> </ul>	<a href="#">Rapid review: What COVID-19 testing requirements and/or recommendations do high-income countries currently have in place in healthcare and long-term care settings?</a>	Rapid review	2022-06-27 (published 2022-07-18)	National Collaborating Centre for Methods and Tools (NCCMT)